Lynparza (olaparib tablets – AstraZeneca) — Cigna
Pancreatic Cancer – Maintenance Therapy
Initial criteria
- Patient is age ≥ 18 years
- Patient has germline BRCA mutation-positive metastatic disease
- Disease has not progressed on at least 16 weeks of treatment with first-line platinum-based chemotherapy
Approval duration
1 year